<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">To explain the unexpected observation that asthma patients and chronic obstructive pulmonary disease patients appear resistant to COVID-19, it is postulated that;
 <list list-type="simple" id="l0005">
  <list-item id="o0005">
   <label>1)</label>
   <p id="p0050">SARS-CoV-2/COVID-19 has two calcium-dependent fusion peptide/fusion loop (FL) domains of that is highly homologous to SARS-CoV-1,</p>
  </list-item>
  <list-item id="o0010">
   <label>2)</label>
   <p id="p0055">The substrate recognition site(s) for cleavage by the requisite cell surface protease TMPRSS2 have a conserved SRCR (scavenger receptor cysteine-rich) domain and a LDLRA (LDL receptor class A) domain that utilize calcium to mediate binding to the SARS-CoV-2 (COVID-19) spike protein (i.e., the ligand),</p>
  </list-item>
  <list-item id="o0015">
   <label>3)</label>
   <p id="p0060">SARS-CoV-2 (COVID-19) infection is, and has been disrupted by exposure to calcium chelating agents such as EDTA in nebulizer medications inhaled by asthma patients to either directly interrupt the cleavage of the S protein by TMPS332 and/or impede the calcium-dependent fusion of SARS-CoV-2 (COVID-19) virions with the host membrane via FL1 and FL2 peptide domains, and</p>
  </list-item>
  <list-item id="o0020">
   <label>4)</label>
   <p id="p0065">Replacement of SARS-CoV-2 S protein amino acids 816 to 855 with HC0V-229E amino acids 923 to 928 may lead to a live attenuated SARS-CoV-2 hybrid strain suitable for vaccination to generating protective antibodies.</p>
  </list-item>
 </list>
</p>
